Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: Association of TREK1 and treatment resistance in the STAR*D study

Neuropsychopharmacology

Volumn 33, Issue 12, 2008, Pages 2810-2819

  Perlis, Roy H ^a   Moorjani, Priya ^a   Fagerness, Jesen ^a   Purcell, Shaun ^a   Trivedi, Madhukar H ^b   Fava, Maurizio ^a   Rush, A John ^b   Smoller, Jordan W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Depression; Genetic; SSRI; Treatment resistant

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; DNA; LITHIUM; MIRTAZAPINE; NORTRIPTYLINE; SERTRALINE; THYROXINE; VENLAFAXINE;

ADULT; AGED; ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE LOCUS; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 50249189084     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.6     Document Type: Article

References (46)

1. Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J et al (2001). High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 98: 581-584.
2. Crowley JJ, Brodkin ES, Blendy JA, Berrettini WH, Lucki I (2006). Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology 31: 2433-2442.
3. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ et al (2002). The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 63: 963-971.
4. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D (2005). Efficiency and power in genetic association studies. Nat Genet 37: 1217-1223.
5. Fava M (2003). Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53: 649-659.
6. Fava M, Davidson KG (1996). Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19: 179-200.
7. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA et al (2003). Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26: 457-494, x.
8. Fink M, Duprat F, Lesage F, Reyes R, Romey G, Heurteaux C et al (1996). Cloning, functional expression and brain localization of a novel unconventional outward rectifier K+ channel. EMBO J 15: 6854-6862.
9. Gordon JA, Hen R (2006). TREKing toward new antidepressants. Nat Neurosci 9: 1081-1083.
10. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
11. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thümmler S, Peng XD et al (2006). Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 9: 1134-1141.
12. Honore E (2007). The neuronal background K2P channels: focus on TREK1. Nat Rev Neurosci 8: 251-261.
13. Kennard LE, Chumbley JR, Ranatunga KM, Armstrong SJ, Veale EL, Mathie A (2005). Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol 144: 821-829.
14. Lavori PW, Rush AJ, Wisniewski SR, Alpert J, Fava M, Kupfer DJ et al (2001). Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry 50: 792-801.
15. Lopes CM, Rohacs T, Czirjak G, Balla T, Enyedi P, Logothetis DE (2005). PIP2 hydrolysis underlies agonist-induced inhibition and regulates voltage gating of two-pore domain K+ channels. J Physiol 564: 117-129.
16. Malhotra AK, Murphy Jr GM, Kennedy JL (2004). Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161: 780-796.
17. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF et al (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78: 804-814.
18. Murbartian J, Lei Q, Sando JJ, Bayliss DA (2005). Sequential phosphorylation mediates receptor- and kinase-induced inhibition of TREK-1 background potassium channels. J Biol Chem 280: 30175-30184.
19. Murphy Jr GM, Kremer C, Rodrigues HE, Schatzberg AF (2003). Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 160: 1830-1835.
20. Neale BM, Sham PC (2004). The future of association studies: gene-based analysis and replication. Am J Hum Genet 75: 353-362.
21. Ott J, Hoh J (2003). Set association analysis of SNP case-control and microarray data. J Comput Biol 10: 569-574.
22. Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH et al (2007). Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 64: 689-697.
23. Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336.
24. Purcell S, Neale BM, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al (2007). PLINK: a toolset for whole genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
25. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC et al (2006a). An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 59: 493-501.
26. Rush AJ, Carmody T, Reimitz P (2000). The inventory of depressive symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 9: 45-59.
27. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA et al (2004). Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25: 119-142.
28. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH (1996). The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med 26: 477-486.
29. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN et al (2003). The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54: 573-583.
30. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al (2006b). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-1917.
31. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al (2006c). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354: 1231-1242.
32. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809.
33. Schafer WR (1999). How do antidepressants work? Prospects for genetic analysis of drug mechanisms. Cell 98: 551-554.
34. Serretti A, Cusin C, Rausch JL, Bondy B, Smeraldi E (2006). Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. Psychiatry Res 145: 61-65.
35. Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim YM, Tsan G et al (2002). Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor. Mol Psychiatry 7: 579-593.
36. Souery D, Papakostas GI, Trivedi MH (2006). Treatment-resistant depression. J Clin Psychiatry 67(Suppl 6): 16-22.
37. Sullivan PF (2007). Spurious genetic associations. Biol Psychiatry 61: 1121-1126.
38. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M et al (2006). Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311: 77-80.
39. Talley EM, Solorzano G, Lei Q, Kim D, Bayliss DA (2001). CNS distribution of members of the two-pore-domain (KCNK) potassium channel family. J Neurosci 21: 7491-7505.
40. Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J (1998). Outcome definitions and predictors in depression. Psychother Psychosom 67: 266-270.
41. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D et al (2006a). Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354: 1243-1252.
42. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T et al (2004). The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 34: 73-82.
43. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al (2006b). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
44. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9: 519-525.
45. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840-1847.
46. Wisniewski SR, Fava M, Trivedi MH, Thase ME, Warden D, Niederehe G et al. Which second step treatments are acceptable to depressed outpatients and their clinicians? A STAR*D report. Am J Psychiatry (in press).